My watch list  

Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market

GBI Research has released its pharmaceutical research, “Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market”, which provides insights into gout therapeutics sales and price forecasts until 2017. The report also delves deep into global gout treatment usage patterns. Furthermore, the geographical distribution of the gout therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) is also provided in the report. The report also provides insights into the gout therapeutics R&D pipeline and the promising future blockbusters by 2017. The report provides an in-depth analysis of acute and chronic gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also covers the profiles of major biopharmaceutical companies in this therapeutics segment. Finally, analysis of mergers and acquisitions, and licensing agreements involving gout therapeutics, is also provided.

GBI Research analysis showed that the global gout therapeutics market was estimated at $542.6m in 2010, with a year-on-year growth rate of 7% between 2002 and 2010. The gout therapeutics market is expected to shift towards biologics that are more efficient and safe compared to conventional therapies. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of approximately 16.3% between 2010 and 2017, to record a sales value of approximately $1,561.3m. The gout therapeutics market had only generics until the launch of Colcrys (colchicine) and TMX 67 (febuxostat) in 2009 and 2010 respectively. In-depth analysis of the report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of experts.

Report Highlights
GBI Research, the leading business intelligence provider, has released its latest research, “Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market”. It provides in-depth analysis of the drivers and barriers that affect the global musculoskeletal therapeutics market. The report analyzes the markets for gout therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report covers revenue, annual cost of treatment and treatment usage patterns, and their forecasts until 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides profiles of the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

High Growth Rate and Launch of High Priced Drugs Have Made the Gout Therapeutics Market Attractive

The global gout therapeutics market is a fast growing market. In 2010, the global gout therapeutics market was worth $542.6m in terms of revenue, which is forecast to grow to $1,561.3m by 2017, showing a growth rate of 16.3% between 2010 and 2017. The prevalence of gout has been increasing continuously since 2002. Consequently, the gout therapeutics market has been growing at a rapid pace over the years, and is expected to accelerate in the coming years. Furthermore, the launch of expected blockbuster drugs such as TMX 67 and Krystexxa, along with the presence of a few promising biologics in the late drug development stage, would drive this growth. As a result, the market will continue to remain fast growing, thereby attracting major pharmaceutical companies to this therapy area.

Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017

Source: GBI Research, American College of Rheumatology, CDC

The gout therapeutics market is expected to grow at a CAGR of 16.3% between 2010 and 2017.

Limited Number of Approved Therapies Would Create Concentrated Patient Pools

The number of gout patients is increasing year on year, and currently there are only three approved drugs in the market – Colcrys (colchicine), TMX 67 (febuxostat) and Krystexxa (pegloticase). Better efficacy and safety profiles of these drugs over generics such as non-steroidal anti inflammatory drugs (NSAID), corticosteroids, allopurinol and probenecid create a remarkable scope for gout therapeutics in the future. There is a sharp increase in the number of patients who are unable to respond to the conventional treatment for chronic gout. Therefore Krystexxa could target a more focused patient pool, refractory to conventional allopurinol therapy, thereby providing a better alternative biologic treatment option.

Strategic Consolidations Have Led to the Entry of New Players in the Musculoskeletal Disorders Therapeutics Market

In the past five to six years many pharmaceutical companies have improved their product profiles with respect to the musculoskeletal disorders therapeutics market. This is due to strategic deals with the aim of introducing new products with better efficacy and safety profiles into the market. Many pharmaceutical companies have either acquired or signed licensing deals with companies possessing potential products for the gout therapeutics market. The acquisitions of worldwide rights of Pegsiticase from EnzymeRx by 3SBio, and the pharmaceutical products portfolio from AstraZeneca by BioPhausia, have been the major acquisitions in the gout therapeutics market. Under licensing agreements the highest valued deal was a licensing agreement between XOMA Ltd and Les Laboratoires Servier to develop and commercialize XOMA 052. In addition, Menarini Group has entered into a licensing agreement with Ipsen to market Adenuric (febuxostat) in 41 countries including Europe, Russia, and countries west of Russia. These strategic consolidations have allowed pharmaceutical companies such as Ipsen Pharmaceuticals, Menarini Group, 3SBio and XOMA Ltd to enter the market.

These strategic consolidations will help the acquirer and licensee companies to diversify their profiles by entering into the gout therapeutics market, which will in turn make the market more competitive. These consolidations will also help the companies to generate revenues, thereby increasing the total revenue of the global gout therapeutics market.

Pharmacy / Drugs   Market study
Year:   2011
Publisher:   GBI Research
Price:   3,500.00€
More about GBI Research
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE